Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.

Rachelle S. Doody, Martin Farlow, Paul S. Aisen, Disease Cooperative Study Data Analysis Alzheimer's Disease Cooperative Study Data Analysis

Research output: Contribution to journalArticle

41 Citations (Scopus)
Original languageEnglish
Pages (from-to)1460
Number of pages1
JournalNew England Journal of Medicine
Volume370
Issue number15
StatePublished - 2014

Fingerprint

solanezumab
Antibodies, Monoclonal, Humanized
Amyloid beta-Peptides
Alzheimer Disease
bapineuzumab

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Doody, R. S., Farlow, M., Aisen, P. S., & Alzheimer's Disease Cooperative Study Data Analysis, D. C. S. D. A. (2014). Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. New England Journal of Medicine, 370(15), 1460.

Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. / Doody, Rachelle S.; Farlow, Martin; Aisen, Paul S.; Alzheimer's Disease Cooperative Study Data Analysis, Disease Cooperative Study Data Analysis.

In: New England Journal of Medicine, Vol. 370, No. 15, 2014, p. 1460.

Research output: Contribution to journalArticle

Doody, RS, Farlow, M, Aisen, PS & Alzheimer's Disease Cooperative Study Data Analysis, DCSDA 2014, 'Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.', New England Journal of Medicine, vol. 370, no. 15, pp. 1460.
Doody RS, Farlow M, Aisen PS, Alzheimer's Disease Cooperative Study Data Analysis DCSDA. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. New England Journal of Medicine. 2014;370(15):1460.
Doody, Rachelle S. ; Farlow, Martin ; Aisen, Paul S. ; Alzheimer's Disease Cooperative Study Data Analysis, Disease Cooperative Study Data Analysis. / Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. In: New England Journal of Medicine. 2014 ; Vol. 370, No. 15. pp. 1460.
@article{70dbfc59a0d44e4a81d8d2593d20387a,
title = "Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.",
author = "Doody, {Rachelle S.} and Martin Farlow and Aisen, {Paul S.} and {Alzheimer's Disease Cooperative Study Data Analysis}, {Disease Cooperative Study Data Analysis}",
year = "2014",
language = "English",
volume = "370",
pages = "1460",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "15",

}

TY - JOUR

T1 - Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease.

AU - Doody, Rachelle S.

AU - Farlow, Martin

AU - Aisen, Paul S.

AU - Alzheimer's Disease Cooperative Study Data Analysis, Disease Cooperative Study Data Analysis

PY - 2014

Y1 - 2014

UR - http://www.scopus.com/inward/record.url?scp=84898887456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898887456&partnerID=8YFLogxK

M3 - Article

C2 - 24716687

AN - SCOPUS:84898887456

VL - 370

SP - 1460

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 15

ER -